Future Immunotherapy Response Monitoring will impact treatment and survival of cancer patients
| Reference number | |
| Coordinator | RISE Research Institutes of Sweden AB |
| Funding from Vinnova | SEK 3 000 000 |
| Project duration | April 2024 - March 2026 |
| Status | Ongoing |
| Venture | Swelife - Collaboration project for better health |
| Call | Swelife - Collaborative projects for better health autumn 2023 |
Purpose and goal
The project will develop a simple method to monitor treatment response in lung cancer patients. Tumor-specific mutations will be quantified in circulating tumor DNA from blood samples instead of relying on current X-ray examinations. The method will be validated on samples from lung cancer patients.
Expected effects and result
The project anticipates several notable outcomes: Cost-effective personalized treatment achieved through measuring circulating DNA in blood samples, Improved treatment monitoring by utilizing patients´ specific tumor mutations to track treatment response, reduced risk of adverse effects by clearer monitoring leading to decreased risks, and economic savings accomplished through effective monitoring of treatment.
Planned approach and implementation
The project structure is organized into 5 work packages where WP1 handles project management and dissemination of results, WP2 manages patient selection and choosing the mutations to measure, WP3 develops personalized monitoring of circulating tumor DNA, WP4 measures tumor burden, and WP5 focuses on business development.